Gretchen R. Haggerty
Gretchen R. Haggerty's purchase track record
Gretchen R. Haggerty has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2026 | ATMU | $110K | -10.8% | pending | — |
| 8/6/2025 | TFX | $57K | +11.6% | -4.9% | +8.5% |
| 8/23/2024 | ATMU | $200K | +29.7% | +10.0% | +6.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Atmus Filtration Shares Fall as JP Morgan Cuts Price Target. Atmus Filtration Technologies shares dropped recently alongside other small-cap names. JP Morgan maintained an Overweight rating but lowered its price target to $54. This move aligns with the stock trading near its support level, reflecting current market caution.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JCI Sees AI Data Center Cooling Growth, Analysts Maintain Coverage. Johnson Controls is positioning itself to capture growth in the expanding data center cooling market, driven by AI and GPU heat loads. Analysts have maintained their coverage of the company, noting its role in U.S. manufacturing and AI infrastructure buildouts. The company's cooling solutions are in high demand as hyperscale data center capacity continues to expand.
Transaction History
| TFX | ▲ Buy | Grant | 1,090 | $0 | 5/15/2026 | View on chart |
| ATMU | ▲ Buy | Open Market | 100 | $6K | 5/12/2026 | View on chart |
| ATMU | ▲ Buy | Open Market | 1 | $56 | 5/12/2026 | View on chart |
| ATMU | ▲ Buy | Open Market | 1,872 | $104K | 5/12/2026 | View on chart |
| ATMU | ▲ Buy | Grant | 2,619 | $0 | 5/12/2026 | View on chart |
| JCI | ▲ Buy | Grant | 1,285 | $0 | 3/4/2026 | View on chart |
| JCI | ▼ Sell | Tax Withholding | 1,115 | $156K | 3/4/2026 | View on chart |
| TFX | ▲ Buy | Open Market | 200 | $23K | 8/6/2025 | View on chart |
| TFX | ▲ Buy | Open Market | 300 | $34K | 8/6/2025 | View on chart |
| ATMU | ▲ Buy | Grant | 3,886 | $0 | 5/20/2025 | View on chart |
| TFX | ▲ Buy | Grant | 1,051 | $0 | 5/9/2025 | View on chart |
| JCI | ▲ Buy | Grant | 2,287 | $0 | 3/12/2025 | View on chart |
| JCI | ▼ Sell | Tax Withholding | 1,416 | $111K | 3/12/2025 | View on chart |
| ATMU | ▲ Buy | Open Market | 5,849 | $200K | 8/23/2024 | View on chart |
| ATMU | ▲ Buy | Grant | 4,565 | $0 | 5/14/2024 | View on chart |
| TFX | ▲ Buy | Grant | 649 | $0 | 5/7/2024 | View on chart |
| JCI | ▲ Buy | Grant | 2,889 | $0 | 3/13/2024 | View on chart |
| JCI | ▼ Sell | Tax Withholding | 1,401 | $86K | 3/9/2024 | View on chart |
| ATMU | ▲ Buy | Grant | 4,624 | — | 8/14/2023 | View on chart |
| ATMU | ▲ Buy | Grant | 4,844 | — | 6/2/2023 | View on chart |
| TFX | ▲ Buy | Grant | 527 | $0 | 5/9/2023 | View on chart |
| JCI | ▲ Buy | Grant | 2,843 | $0 | 3/9/2023 | View on chart |
| JCI | ▲ Buy | Option Exercise | 1,372 | $87K | 3/8/2023 | View on chart |
| TFX | ▲ Buy | Grant | 399 | $0 | 5/3/2022 | View on chart |
| JCI | ▼ Sell | Tax Withholding | 1,398 | $88K | 3/9/2022 | View on chart |
| JCI | ▲ Buy | Grant | 2,786 | $0 | 3/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate
Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate. Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.